MYC and osteosarcoma: For example, JQ1 and histone deacetylase inhibitors exert synergistic anticancer effects against pancreatic cancer [32], mantle cell lymphoma [33] and Myc-induced murine lymphoma [34] both in vitro and in vivo, and JQ1 in combination with the CDK inhibitor flavopiridol or the mTOR inhibitor rapamycin synergistically induces osteosarcoma cell apoptosis [35, 36].